Literature DB >> 8124218

Possible imbalance of the immuno-hormonal axis in multiple myeloma.

H Everaus1, M Hein, K Zilmer.   

Abstract

A comparative study of some immunologic aspects and hormonal balance was performed on 49 multiple myeloma (MM) patients and 29 healthy persons. Functional immunoregulatory imbalances were evident in the majority of patients with MM, as demonstrated by a significant reduction in the mitogenic response of peripheral blood lymphocytes (PBL) to phytohemagglutinin, increased mean stimulation indices of PBL to pisum sativatum agglutinin, wheat germ agglutinin (WGA) and dextran sulphate. Our results appear to provide important evidence in support of the existence of hormonal imbalance in MM: increased cortisol levels, augmented concentrations of follicle stimulating hormone, luteinizing hormone and 17 beta-estradiol and an increased estrogen to androgen ratio in male patients; decreased estrogen values and estrogen to androgen ratios were evident in female patients. Triiodothyronine and thyroxine mean concentrations were also found to be markedly diminished in MM patients. Our studies suggest some potentially important interactions between the immune and endocrine systems in multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8124218     DOI: 10.3109/10428199309067940

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

1.  Dietary acrylamide intake and the risk of lymphatic malignancies: the Netherlands Cohort Study on diet and cancer.

Authors:  Mathilda L Bongers; Janneke G F Hogervorst; Leo J Schouten; R Alexandra Goldbohm; Harry C Schouten; Piet A van den Brandt
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

2.  Anthropometric, behavioral, and female reproductive factors and risk of multiple myeloma: a pooled analysis.

Authors:  Sophia S Wang; Jenna Voutsinas; Ellen T Chang; Christina A Clarke; Yani Lu; Huiyan Ma; Dee West; James V Lacey; Leslie Bernstein
Journal:  Cancer Causes Control       Date:  2013-04-09       Impact factor: 2.532

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.